<?xml version="1.0" encoding="ASCII"?><!DOCTYPE article PUBLIC "-//BEILSTEIN-INSTITUT//DTD Journal Article DTD v0.4.4 20130724//EN" "https://www.beilstein-journals.org/bjoc/content/xml/journalarticle.v044.dtd">
<article locale="en" public-id="1860-5397-5-28" publisher="Beilstein-Institut" journal="Beilstein Journal of Organic Chemistry" journal-abbreviated="Beilstein J. Org. Chem." journal-code="bjoc" issn="1860-5397" coden="BJOCBH" year="2009" volume="5" article="28" type="full-research-paper">
<author first-name="Graham" middle-names="R" last-name="Lawton" affiliations="a1"/>
<author first-name="Haitao" last-name="Ji" affiliations="a1"/>
<author first-name="Pavel" last-name="Mart&#225;sek" affiliations="a2 a3"/>
<author first-name="Linda" middle-names="J" last-name="Roman" affiliations="a2"/>
<author first-name="Richard" middle-names="B" last-name="Silverman" email="r-silverman@northwestern.edu" affiliations="a1" corresponding-author="yes"/>
<affiliation id="a1" institution-required="yes">Department of Chemistry, Center for Molecular Innovation and Drug Discovery, and Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208-3113 (USA)</affiliation>
<affiliation id="a2" institution-required="yes">Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas (USA)</affiliation>
<affiliation id="a3" institution-required="yes">Department of Pediatrics and Center for Applied Genomics, 1st School of Medicine, Charles University, Prague, Czech Republic</affiliation>
<editor first-name="Sabine" last-name="Flitsch" role="associate-editor"/>
<submission-date day="27" month="3" year="2009" hour="0" minute="0"/>
<acceptance-date day="14" month="5" year="2009" hour="0" minute="0"/>
<publication-date day="4" month="6" year="2009" hour="0" minute="0"/>
<title>
<chunk>Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase</chunk>
</title>
<keyword>
<chunk>2-aminothiazole</chunk>
</keyword>
<keyword>
<chunk>4-aminothiazole</chunk>
</keyword>
<keyword>
<chunk>nitric oxide synthase inhibitor</chunk>
</keyword>
<keyword>
<chunk>nNOS</chunk>
</keyword>
<abstract-section>
<paragraph>
<chunk>Highly potent and selective inhibitors of neuronal nitric oxide synthase (nNOS) possessing a 2-aminopyridine group were recently designed and synthesized in our laboratory and were shown to have significant in vivo efficacy. In this work, analogs of our lead compound possessing 2- and 4-aminothiazole rings in place of the aminopyridine were synthesized. The less basic aminothiazole rings will be less protonated at physiological pH than the aminopyridine ring, and so the molecule will carry a lower net charge. This could lead to an increased ability to cross the blood-brain barrier thereby increasing the in vivo potency of these compounds. The 2-aminothiazole-based compound was less potent than the 2-aminopyridine-based analogue. 4-Aminothiazoles were unstable in water, undergoing tautomerization and hydrolysis to give inactive thiazolones.</chunk>
</paragraph>
</abstract-section>
<abstract-graphic public-id="1860-5397-5-28-graphical-abstract"/>
<external-link type="doi" public-id="10.3762/bjoc.5.28"/>
<section>
<title>
<chunk>Introduction</chunk>
</title>
<paragraph>
<chunk>Neuronal nitric oxide synthase (nNOS) is the constitutive isoform of nitric oxide synthase (NOS) found in the CNS. It is believed to play a role in many neurological diseases, including Parkinson&#8217;s disease </chunk>
<link target="b1"/>
<chunk>, Alzheimer&#8217;s disease </chunk>
<link target="b2"/>
<chunk>, damage due to stroke </chunk>
<link target="b3"/>
<chunk>, and cerebral palsy caused by pre-natal hypoxia </chunk>
<link target="b4"/>
<chunk>. To fully explore the role nNOS plays in these and other diseases, and to design inhibitors with therapeutic value, nNOS must be inhibited selectively without inhibition of the other isoforms, inducible NOS (iNOS) and endothelial NOS (eNOS); inhibition of eNOS could lead to side effects such as hypertension </chunk>
<link target="b5"/>
<chunk>.</chunk>
</paragraph>
<paragraph>
<chunk>Designing therapeutically useful nNOS-selective inhibitors is a difficult task as the substrate for all three isoforms is L-arginine, and so they have similar active sites. In recent years, we have developed several potent and highly selective inhibitors of nNOS that have solved this problem by exploiting subtle differences among the isoforms </chunk>
<link target="b6"/>
<chunk>. In addition, the active site of nNOS is polar with multiple acidic groups, and so most inhibitors that bind with high potency are polar with multiple basic groups. In general, highly charged, hydrophilic molecules do not diffuse passively across the blood-brain barrier (BBB), thus limiting the concentration of inhibitor in the CNS </chunk>
<link target="b7"/>
<chunk>.</chunk>
</paragraph>
<paragraph>
<chunk>Recently, a new strategy for fragment-based de novo design, called fragment hopping, was described and utilized to design </chunk>
<chunk bold="yes">1</chunk>
<chunk> (</chunk>
<link target="f1"/>
<chunk>), a new nNOS-selective inhibitor </chunk>
<link target="b8"/>
<chunk>, which showed nanomolar nNOS inhibitory potency and more than 1000-fold selectivity over eNOS. Lead compound </chunk>
<chunk bold="yes">1</chunk>
<chunk> was then evolved into highly potent and selective inhibitor </chunk>
<chunk bold="yes">2</chunk>
<chunk> with better drug-like properties </chunk>
<link target="b9"/>
<chunk>. Intravenous administration of </chunk>
<chunk bold="yes">2</chunk>
<chunk> resulted in significant protection against neuronal damage in a cerebral palsy rabbit model </chunk>
<link target="b10"/>
<chunk>.</chunk>
</paragraph>
<float target="f1"/>
<paragraph>
<chunk>Replacement of basic functional groups of our lead molecule with less basic groups will reduce the overall charge on the molecule and should increase BBB penetration, leading to greater in vivo efficacy. The conjugate acid of the ring nitrogen of the aminopyridine has a pK</chunk>
<chunk subscript="yes">a</chunk>
<chunk> &#8776; 7 </chunk>
<link target="b11"/>
<chunk>, therefore, the ring will be partially protonated and only partially charged in biological systems. Crystal structures of </chunk>
<chunk bold="yes">2</chunk>
<chunk> bound to the active site of nNOS show that the aminopyridine group interacts with a glutamate residue (Glu592, rat nNOS), presumably via hydrogen bonding and electrostatic interactions </chunk>
<link target="b8"/>
<link target="b12"/>
<chunk>. The aminopyridine ring nitrogen must be protonated for this interaction to occur. Replacement of the aminopyridine with less basic aminothiazoles (</chunk>
<chunk bold="yes">3</chunk>
<chunk> and </chunk>
<chunk bold="yes">4</chunk>
<chunk>), whose ring nitrogens have pK</chunk>
<chunk subscript="yes">a</chunk>
<chunk> values &#8776; 6, should reduce the overall charge on the molecule at physiological pH for more efficient bioavailability. In the acidic environment of the nNOS active site, however, protonation should occur to allow the aminothiazole to interact with the active site glutamate and maintain tight binding. The methyl group at the 4 position on the aminopyridine ring contributes to binding through an interaction with a hydrophobic pocket in the nNOS active site. The R-groups at the 5-position of </chunk>
<chunk bold="yes">4</chunk>
<chunk> should allow us to probe the hydrophobic binding pocket defined by P565, A566, V567, and F584 in the substrate binding site and optimize this interaction. </chunk>
<link target="f2"/>
<chunk> shows the docking mode for </chunk>
<chunk bold="yes">3</chunk>
<chunk> and </chunk>
<chunk bold="yes">4a</chunk>
<chunk> in rat nNOS.</chunk>
</paragraph>
<float target="f2"/>
<paragraph>
<chunk>Initially, attempts were made to construct </chunk>
<chunk bold="yes">3</chunk>
<chunk> and </chunk>
<chunk bold="yes">4</chunk>
<chunk> using chemistry analogous to that used to construct </chunk>
<chunk bold="yes">2</chunk>
<chunk> (</chunk>
<link target="s1"/>
<chunk>). Briefly, Boc protected 2-amino-4-methylthiazoles, and 4-amino-2-methylthiazoles were treated with </chunk>
<chunk italic="yes">n</chunk>
<chunk>-butyllithium, and then epoxide </chunk>
<chunk bold="yes">5</chunk>
<chunk> was added in an attempt to form </chunk>
<chunk italic="yes">trans</chunk>
<chunk> alcohols </chunk>
<chunk bold="yes">6</chunk>
<chunk> and </chunk>
<chunk bold="yes">7</chunk>
<chunk>. However, this method failed to give any of the desired products.</chunk>
</paragraph>
<float target="s1"/>
<paragraph>
<chunk>A successful route to 2-aminothiazoles is outlined in </chunk>
<link target="s2"/>
<chunk>. Epoxide </chunk>
<chunk bold="yes">5</chunk>
<chunk> was opened with allylmagnesium bromide, and the resulting alcohol was protected as a TBS ether. The double bond was converted to an epoxide, which was then opened with bromide under acidic conditions </chunk>
<link target="b13"/>
<chunk>. A mixture of diastereomers was formed, but both were oxidized to &#945;-bromoketone </chunk>
<chunk bold="yes">12</chunk>
<chunk>. Condensation with thiourea gave the 2-aminothiazole (</chunk>
<chunk bold="yes">13</chunk>
<chunk>). Diprotection of the amine with Boc groups and deprotection of the TBS ether gave </chunk>
<chunk italic="yes">trans</chunk>
<chunk>-alcohol </chunk>
<chunk bold="yes">15</chunk>
<chunk>. A Mitsunobu reaction was used to install a nitrogen atom in the form of a phthalimide group with the desired </chunk>
<chunk italic="yes">cis</chunk>
<chunk>-stereochemistry. The amine was deprotected, but that resulted in the loss of one of the Boc groups to give </chunk>
<chunk bold="yes">17</chunk>
<chunk>.</chunk>
</paragraph>
<float target="s2"/>
<paragraph>
<chunk>Ethyl glycinate was alkylated with </chunk>
<chunk italic="yes">p</chunk>
<chunk>-chlorobenzyl chloride to give secondary amine </chunk>
<chunk bold="yes">18</chunk>
<chunk>, which was protected with a Boc group. The ester was hydrolyzed and converted to the Weinreb amide. Reduction with LAH gave aldehyde </chunk>
<chunk bold="yes">22</chunk>
<chunk> (</chunk>
<link target="s3"/>
<chunk>).</chunk>
</paragraph>
<paragraph>
<chunk>Compounds </chunk>
<chunk bold="yes">17</chunk>
<chunk> and </chunk>
<chunk bold="yes">22</chunk>
<chunk> were condensed to form an imine prior to the addition of NaHB(OAc)</chunk>
<chunk subscript="yes">3</chunk>
<chunk>, giving secondary amine </chunk>
<chunk bold="yes">23</chunk>
<chunk>. Removal of the Boc groups with acid gave </chunk>
<chunk bold="yes">3</chunk>
<chunk> as a tetrahydrochloride salt.</chunk>
</paragraph>
<float target="s3"/>
<paragraph>
<chunk>The 4-aminothiazoles were constructed as shown in </chunk>
<link target="s4"/>
<chunk>. Treatment of acetonitrile with LDA followed by addition of epoxide </chunk>
<chunk bold="yes">5</chunk>
<chunk> gave </chunk>
<chunk italic="yes">trans</chunk>
<chunk>-alcohol </chunk>
<chunk bold="yes">24</chunk>
<chunk> </chunk>
<link target="b14"/>
<chunk>. The nitrile group was converted to a thioamide using ammonium sulfide </chunk>
<link target="b15"/>
<chunk>. The thioamide was condensed with either ethyl bromopyruvate or an epoxide (</chunk>
<chunk bold="yes">30</chunk>
<chunk>) </chunk>
<link target="b16"/>
<chunk>. Condensation produces an equivalent of acid, which was sufficient to cleave the Boc group. Buffering the reaction resulted in incomplete conversion to the thiazole because acidic conditions are necessary to catalyze the final dehydration step in the reaction </chunk>
<link target="b17"/>
<chunk>. However, the problem was solved by simply neutralizing the mixture on completion of the reaction and reprotecting the amine. The resulting esters (</chunk>
<chunk bold="yes">26a</chunk>
<chunk>, R = H; </chunk>
<chunk bold="yes">26b</chunk>
<chunk>, R= Me; </chunk>
<chunk bold="yes">26c</chunk>
<chunk>, R = </chunk>
<chunk italic="yes">i</chunk>
<chunk>-Pr) were hydrolyzed, and a Curtius rearrangement performed in </chunk>
<chunk italic="yes">tert</chunk>
<chunk>-butanol gave the protected 4-aminothiazoles (</chunk>
<chunk bold="yes">7a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk>) </chunk>
<link target="b18"/>
<chunk>. Unlike the case of the aminopyridine analogues </chunk>
<link target="b19"/>
<chunk>, the aminothiazole does not need to be diprotected to allow the Mitsunobu reaction with phthalimide as the nucleophile to proceed (</chunk>
<chunk bold="yes">28a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk>). This is presumably because the thiazole nitrogen is less nucleophilic. Cleavage of the phthalimide group gave amines </chunk>
<chunk bold="yes">29a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk>.</chunk>
</paragraph>
<float target="s4"/>
<paragraph>
<chunk>The syntheses of </chunk>
<chunk bold="yes">4a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk> were completed by reductive amination followed by removal of the Boc groups (</chunk>
<link target="s5"/>
<chunk>). Although the final deprotection did give the desired product, as evidenced by mass spectrometry, on addition of water, the product decomposed. The 4-aminothiazole tautomerized to the thiazoline, which was then hydrolyzed </chunk>
<link target="b20"/>
<chunk>. Test reactions on model 4-aminothiazoles prepared by an analogous route showed that none of the desired product remains in aqueous solution. Further degradation occurred following hydrolysis, and the products could not be identified.</chunk>
</paragraph>
<float target="s5"/>
</section>
<section>
<title>
<chunk>Results and Discussion</chunk>
</title>
<paragraph>
<chunk>Compound </chunk>
<chunk bold="yes">3</chunk>
<chunk> was tested for in vitro activity against rat nNOS </chunk>
<link target="b21"/>
<chunk>, bovine eNOS </chunk>
<link target="b22"/>
<chunk>, and murine iNOS </chunk>
<link target="b23"/>
<chunk> using a hemoglobin capture assay </chunk>
<link target="b24"/>
<chunk>, giving </chunk>
<chunk italic="yes">K</chunk>
<chunk subscript="yes">i</chunk>
<chunk> values of 10 &#956;M, 1 mM and 50 &#956;M, respectively. This corresponds to a significant loss in potency toward nNOS relative to lead compound </chunk>
<chunk bold="yes">2</chunk>
<chunk> [</chunk>
<chunk italic="yes">K</chunk>
<chunk subscript="yes">i</chunk>
<chunk>(nNOS) = 0.085 &#956;M, </chunk>
<chunk italic="yes">K</chunk>
<chunk subscript="yes">i</chunk>
<chunk>(eNOS) = 85 &#956;M, </chunk>
<chunk italic="yes">K</chunk>
<chunk subscript="yes">i</chunk>
<chunk>(iNOS] = 9 &#956;M), suggesting that the aminopyridine ring is critical for high affinity binding. It has been shown that the addition of electron-withdrawing groups to a 2-aminopyridine significantly decreases NOS affinity </chunk>
<link target="b25"/>
<chunk>. This is possibly the result of a lowering of the p</chunk>
<chunk italic="yes">K</chunk>
<chunk subscript="yes">a</chunk>
<chunk> such that the ring nitrogen is insufficiently protonated to interact with the glutamate. We had hoped that the high acidity of the active site would protonate the aminothiazole so that it would interact well with the glutamate residue. This may not be the case. An alternative explanation for the loss of potency is that the 2-aminothiazole ring is much smaller than 2-amino-4-methylpyridine. The methyl group at the 4-position of the pyridine ring contributes a significant amount to binding, resulting in a 4-fold increase in potency. There is no functionality in the 2-aminothiazoles to provide a similar hydrophobic interaction. If the 4-aminothiazoles had been stable, the alkyl group in the 5-position could have contributed to binding to restore some of the lost potency.</chunk>
</paragraph>
</section>
<section>
<title>
<chunk>Conclusion</chunk>
</title>
<paragraph>
<chunk>2-Aminothiazole-based nNOS inhibitor </chunk>
<chunk bold="yes">3</chunk>
<chunk> was synthesized via a condensation reaction between thiourea and the appropriate &#945;-bromoketone. However, the inhibitor was less potent than the aminopyridine lead. Nonetheless, the synthetic methodology is useful for the construction of this ring system. 4-Aminothiazole-based inhibitors with various alkyl groups at the thiazole 5-position could be synthesized, but proved to be unstable in aqueous medium. This is a valuable insight for others contemplating this ring system for biological studies. Unfortunately, the use of an aminothiazole in place of the aminopyridine moiety is not a beneficial modification in the case of our nNOS inhibitors. Alternative methods to reduce the overall charge on the molecule are under investigation.</chunk>
</paragraph>
</section>
<album-graphics>
<graphic public-id="1860-5397-5-28-1"/>
<graphic public-id="1860-5397-5-28-i2"/>
<graphic public-id="1860-5397-5-28-i5"/>
</album-graphics>
<figures>
<figure id="f1">
<caption>
<paragraph>
<chunk>Lead compounds </chunk>
<chunk bold="yes">1</chunk>
<chunk> and </chunk>
<chunk bold="yes">2</chunk>
<chunk>; 2- and 4-aminothiazole analogs </chunk>
<chunk bold="yes">3</chunk>
<chunk> and </chunk>
<chunk bold="yes">4a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk>.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-1"/>
</figure>
<figure id="f2">
<caption>
<paragraph>
<chunk>A: The docking conformation of </chunk>
<chunk bold="yes">3</chunk>
<chunk> in the active site of rat nNOS; B: The docking conformation of </chunk>
<chunk bold="yes">4b</chunk>
<chunk> in the active site of rat nNOS. Cofactors heme and H</chunk>
<chunk subscript="yes">4</chunk>
<chunk>B are shown in orange and purple, respectively.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-2"/>
</figure>
</figures>
<schemes>
<scheme id="s1">
<caption>
<paragraph>
<chunk>Attempts to open epoxide </chunk>
<chunk bold="yes">5</chunk>
<chunk> with deprotonated aminothiazoles. i) </chunk>
<chunk italic="yes">n</chunk>
<chunk>-BuLi, 2 equiv, THF, &#8722;78 &#176;C; ii) </chunk>
<chunk bold="yes">5</chunk>
<chunk>, THF, &#8722;78 &#176;C to rt.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-i1"/>
</scheme>
<scheme id="s2">
<caption>
<paragraph>
<chunk>Assembly of 2-aminothiazole fragment. i) AllylMgBr, ether, 0 &#176;C, 15 min.; ii) TBSCl, imidazole, DMF, 35 &#176;C, 16 h; iii) m-CPBA, rt, 48 h; iv) LiBr, AcOH, THF, rt, 16h; v) (COCl)</chunk>
<chunk subscript="yes">2</chunk>
<chunk>, DMSO, TEA, CH</chunk>
<chunk subscript="yes">2</chunk>
<chunk>Cl</chunk>
<chunk subscript="yes">2</chunk>
<chunk>, &#8722;78 &#176;C, 1 h; vi) thiourea, EtOH, reflux, 5 h; vii) Boc</chunk>
<chunk subscript="yes">2</chunk>
<chunk>O (2.5 equiv), DMAP, THF, rt, 16 h; viii) TBAF, THF, rt 16 h; ix) PPh</chunk>
<chunk subscript="yes">3</chunk>
<chunk>, DIAD, phthalimide, THF, rt, 16 h; x) H</chunk>
<chunk subscript="yes">2</chunk>
<chunk>NNH</chunk>
<chunk subscript="yes">2</chunk>
<chunk> (aq), MeOH, rt, 16 h, then 2N HCl, rt, 30 min.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-i2"/>
</scheme>
<scheme id="s3">
<caption>
<paragraph>
<chunk>Synthesis of compound </chunk>
<chunk bold="yes">3</chunk>
<chunk>. i) 4-chlorobenzylchloride, EtOH, reflux, 4 h; ii) Boc</chunk>
<chunk subscript="yes">2</chunk>
<chunk>O, TEA, MeOH, 3 h; iii) 1 N NaOH, MeOH, rt, 4 h; iv) EDC, HOBt, TEA, HN(OMe)Me&#183;HCl, CH</chunk>
<chunk subscript="yes">2</chunk>
<chunk>Cl</chunk>
<chunk subscript="yes">2</chunk>
<chunk>, 16 h; v) LAH, THF, 0 &#176;C, 1 h; vi) (&#177;)-17, CH</chunk>
<chunk subscript="yes">2</chunk>
<chunk>Cl</chunk>
<chunk subscript="yes">2</chunk>
<chunk>, NaHB(OAc)</chunk>
<chunk subscript="yes">3</chunk>
<chunk>, 1 h; vii) 4N HCl, dioxanes, rt, 16 h.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-i3"/>
</scheme>
<scheme id="s4">
<caption>
<paragraph>
<chunk>Assembly of the 4-aminothiazole fragments. i) LiCH</chunk>
<chunk subscript="yes">2</chunk>
<chunk>CN, THF, 0 &#176;C, 4 h; ii) (NH</chunk>
<chunk subscript="yes">4</chunk>
<chunk>)</chunk>
<chunk subscript="yes">2</chunk>
<chunk>S (aq), MeOH, 16 h; iii) ethyl brompyruvate (for R = H) or </chunk>
<chunk bold="yes">30</chunk>
<chunk>, MeOH, reflux, 5 h, then DIEA, Boc</chunk>
<chunk subscript="yes">2</chunk>
<chunk>O, rt, 16 h; iv) 1N NaOH (aq), MeOH, rt, 16 h; v) DPPA, TEA, 3 &#197; mol. sieves, </chunk>
<chunk italic="yes">t</chunk>
<chunk>-BuOH, reflux, 16 h; vi) PPh</chunk>
<chunk subscript="yes">3</chunk>
<chunk>, DIAD, phthalimide, THF, rt, 16 h; vii) H</chunk>
<chunk subscript="yes">2</chunk>
<chunk>NNH</chunk>
<chunk subscript="yes">2</chunk>
<chunk> (aq), MeOH, rt, 16 h, then 2N HCl, rt, 30 min.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-i4"/>
</scheme>
<scheme id="s5">
<caption>
<paragraph>
<chunk>Synthesis of inhibitor </chunk>
<chunk bold="yes">4a</chunk>
<chunk>-</chunk>
<chunk bold="yes">c</chunk>
<chunk>. The 4-aminothiazoles were not stable in water undergoing tautomerization and hydrolysis. i) MeOH, 30 min, then NaHB(OAc)</chunk>
<chunk subscript="yes">3</chunk>
<chunk>, rt, 1 h; ii) 4N HCl, dioxanes, rt, 16 h.</chunk>
</paragraph>
</caption>
<graphic public-id="1860-5397-5-28-i5"/>
</scheme>
</schemes>
<substances>
<substance id="1860-5397-5-28-BETYXZSFUFTOLC-GXSJLCMTSA-N">
<inchi-key>BETYXZSFUFTOLC-GXSJLCMTSA-N</inchi-key>
<inchi>InChI=1S/C12H21N5/c13-4-5-16-11-8-15-7-9(11)6-10-2-1-3-12(14)17-10/h1-3,9,11,15-16H,4-8,13H2,(H2,14,17)/t9-,11+/m0/s1</inchi>
<smiles>C1=CC(=NC(=C1)C[C@H]2CNC[C@H]2NCCN)N</smiles>
<extended-smiles>C1=C(N=C(C=C1)C[C@@H]2[C@@H](CNC2)NCCN)N |(36.56,-67.51,;36.56,-78.45,;46.04,-83.92,;55.51,-78.45,;55.51,-67.51,;46.04,-62.04,;64.96,-83.9,;74.4,-78.45,;84.8,-81.87,;91.27,-73.04,;84.86,-64.16,;74.44,-67.51,;88.13,-92.26,;98.13,-86.57,;107.54,-92.17,;117.09,-86.82,;27.11,-83.9,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:6,5,1,16,15,7,13,11,9,4,10,2,17,8,12,14,3/it:im/rA:17nCCNCCCCNC.eC.oCNCNCCN/rB:d1;s2;d3;s4;s1d5;s4;s2;p7;s9;s10;s11;s9s12;P10;s14;s15;s16;/rC:36,5587,-67,5080,0;36,5587,-78,4520,0;46,0365,-83,9240,0;55,5143,-78,4520,0;55,5143,-67,5080,0;46,0365,-62,0360,0;64,9592,-83,9050,0;27,1139,-83,9050,0;74,4041,-78,4520,0;84,7999,-81,8721,0;91,2651,-73,0419,0;84,8649,-64,1644,0;74,4442,-67,5080,0;88,1319,-92,2566,0;98,1330,-86,5741,0;107,5377,-92,1707,0;117,0869,-86,8243,0;</aux-info>
<molecular-formula>C12H21N5</molecular-formula>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 36.55873 -67.50798 0 0
M  V30 2 C 36.55873 -78.45198 0 0
M  V30 3 N 46.03653 -83.92398 0 0
M  V30 4 C 55.5143 -78.45198 0 0
M  V30 5 C 55.5143 -67.50798 0 0
M  V30 6 C 46.03653 -62.03598 0 0
M  V30 7 C 64.95918 -83.90497 0 0
M  V30 8 N 27.11386 -83.90497 0 0
M  V30 9 C 74.40405 -78.45198 0 0 CFG=1
M  V30 10 C 84.79991 -81.87206 0 0 CFG=2
M  V30 11 C 91.26512 -73.04189 0 0
M  V30 12 N 84.86494 -64.16443 0 0
M  V30 13 C 74.44423 -67.50804 0 0
M  V30 14 N 88.13193 -92.25659 0 0
M  V30 15 C 98.13301 -86.5741 0 0
M  V30 16 C 107.53772 -92.17072 0 0
M  V30 17 N 117.08691 -86.82431 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 1
M  V30 7 1 4 7
M  V30 8 1 2 8
M  V30 9 1 9 7 CFG=1
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 9
M  V30 15 1 10 14 CFG=1
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-1" left="15.795105" right="128.40565" top="54.53943" bottom="101.531586"/>
</substance>
<substance id="1860-5397-5-28-JDRSQGJWTVRNGM-QFBILLFUSA-N">
<inchi-key>JDRSQGJWTVRNGM-QFBILLFUSA-N</inchi-key>
<inchi>InChI=1S/C20H28ClN5/c1-14-8-18(26-20(22)9-14)10-16-12-24-13-19(16)25-7-6-23-11-15-2-4-17(21)5-3-15/h2-5,8-9,16,19,23-25H,6-7,10-13H2,1H3,(H2,22,26)/t16-,19+/m0/s1</inchi>
<smiles>CC1=CC(=NC(=C1)C[C@H]2CNC[C@H]2NCCNCC3=CC=C(C=C3)Cl)N</smiles>
<extended-smiles>C1=C(N=C(C=C1C)C[C@@H]2[C@@H](CNC2)NCCNCC3=CC=C(C=C3)Cl)N |(183.62,-68.08,;183.62,-79.02,;193.1,-84.49,;202.57,-79.02,;202.57,-68.08,;193.1,-62.61,;193.1,-51.7,;212.02,-84.47,;221.46,-79.02,;231.86,-82.44,;238.33,-73.61,;231.92,-64.73,;221.5,-68.08,;235.19,-92.83,;245.19,-87.14,;254.6,-92.74,;264.15,-87.39,;275.51,-93.7,;285.06,-88.35,;294.46,-93.95,;304.01,-88.6,;304.16,-77.66,;294.75,-72.06,;285.2,-77.41,;313.67,-72.33,;174.17,-84.47,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:15,21,25,22,24,17,16,5,1,7,19,13,11,6,20,9,23,4,10,2,26,8,18,12,14,3/E:(2,3)(4,5)/it:im/rA:26nCCNCCCCNC.eC.oCNCNCCCNCCCCCCCCl/rB:d1;s2;d3;s4;s1d5;s4;s2;p7;s9;s10;s11;s9s12;P10;s6;s14;s16;s17;s18;s19;d20;s21;d22;s23;s20d24;s23;/rC:183,6187,-68,0780,0;183,6187,-79,0220,0;193,0965,-84,4940,0;202,5743,-79,0220,0;202,5743,-68,0780,0;193,0965,-62,6060,0;212,0192,-84,4750,0;174,1739,-84,4750,0;221,4641,-79,0220,0;231,8599,-82,4421,0;238,3251,-73,6119,0;231,9250,-64,7344,0;221,5042,-68,0780,0;235,1919,-92,8266,0;193,0965,-51,7000,0;245,1930,-87,1441,0;254,5977,-92,7407,0;264,1469,-87,3943,0;275,5098,-93,7002,0;285,0589,-88,3537,0;294,4637,-93,9504,0;304,0128,-88,6040,0;304,1573,-77,6609,0;294,7526,-72,0643,0;285,2034,-77,4107,0;313,6733,-72,3331,0;</aux-info>
<molecular-formula>C20H28ClN5</molecular-formula>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 183.61874 -68.07799 0 0
M  V30 2 C 183.61874 -79.02199 0 0
M  V30 3 N 193.09653 -84.49397 0 0
M  V30 4 C 202.57431 -79.02199 0 0
M  V30 5 C 202.57431 -68.07799 0 0
M  V30 6 C 193.09653 -62.60597 0 0
M  V30 7 C 212.01918 -84.47498 0 0
M  V30 8 N 174.17386 -84.47498 0 0
M  V30 9 C 221.46405 -79.02199 0 0 CFG=1
M  V30 10 C 231.85989 -82.44206 0 0 CFG=2
M  V30 11 C 238.3251 -73.61188 0 0
M  V30 12 N 231.92496 -64.73442 0 0
M  V30 13 C 221.50424 -68.07803 0 0
M  V30 14 N 235.19191 -92.8266 0 0
M  V30 15 C 193.09653 -51.7 0 0
M  V30 16 C 245.19301 -87.14409 0 0
M  V30 17 C 254.59772 -92.74071 0 0
M  V30 18 N 264.14691 -87.3943 0 0
M  V30 19 C 275.50977 -93.70016 0 0
M  V30 20 C 285.05893 -88.35374 0 0
M  V30 21 C 294.46365 -93.95039 0 0
M  V30 22 C 304.01285 -88.60399 0 0
M  V30 23 C 304.15729 -77.66093 0 0
M  V30 24 C 294.75259 -72.06432 0 0
M  V30 25 C 285.2034 -77.41071 0 0
M  V30 26 Cl 313.67334 -72.3331 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 1
M  V30 7 1 4 7
M  V30 8 1 2 8
M  V30 9 1 9 7 CFG=1
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 9
M  V30 15 1 10 14 CFG=1
M  V30 16 1 6 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 20
M  V30 28 1 23 26
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-1" left="162.8551" right="318.04208" top="51.699997" bottom="102.10159"/>
</substance>
<substance id="1860-5397-5-28-QPODFPBSXPVCMC-XJKSGUPXSA-N">
<inchi-key>QPODFPBSXPVCMC-XJKSGUPXSA-N</inchi-key>
<inchi>InChI=1S/C17H24ClN5S/c18-14-3-1-12(2-4-14)8-20-5-6-22-16-10-21-9-13(16)7-15-11-24-17(19)23-15/h1-4,11,13,16,20-22H,5-10H2,(H2,19,23)/t13-,16+/m0/s1</inchi>
<smiles>C1=C(C=CC(=C1)Cl)CNCCN[C@@H]2CNC[C@@H]2CC3=CSC(=N3)N</smiles>
<extended-smiles>C1(C[C@@H]2[C@@H](CNC2)NCCNCC3=CC=C(C=C3)Cl)=CSC(=N1)N |(45.39,-134.42,;54.83,-139.87,;64.28,-134.42,;74.67,-137.84,;81.14,-129.01,;74.74,-120.13,;64.32,-123.47,;78,-148.22,;88,-142.54,;97.41,-148.14,;106.96,-142.79,;118.32,-149.1,;127.87,-143.75,;137.28,-149.35,;146.82,-144,;146.97,-133.06,;137.56,-127.46,;128.01,-132.81,;156.48,-127.73,;44.24,-123.53,;33.54,-121.26,;28.06,-130.74,;35.39,-138.87,;17.22,-131.88,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:19,23,20,22,15,14,2,17,12,10,3,18,8,21,1,9,5,24,7,16,11,13,6,4/E:(1,2)(3,4)/it:im/rA:24nCCCSCNNC.eC.oCNCNCCNCCCCCCCCl/rB:s1;d1;s3;s4;s1d5;s5;p2;s8;s9;s10;s8s11;P9;s13;s14;s15;s16;s17;d18;s19;d20;s21;s18d22;s21;/rC:45,3858,-134,4170,0;54,8307,-139,8700,0;44,2418,-123,5329,0;33,5370,-121,2576,0;28,0650,-130,7353,0;35,3880,-138,8683,0;17,2187,-131,8753,0;64,2755,-134,4170,0;74,6714,-137,8371,0;81,1366,-129,0069,0;74,7364,-120,1294,0;64,3157,-123,4730,0;78,0034,-148,2216,0;88,0045,-142,5391,0;97,4092,-148,1357,0;106,9584,-142,7893,0;118,3212,-149,0952,0;127,8704,-143,7487,0;137,2751,-149,3454,0;146,8243,-143,9990,0;146,9688,-133,0559,0;137,5641,-127,4593,0;128,0149,-132,8057,0;156,4848,-127,7281,0;</aux-info>
<molecular-formula>C17H24ClN5S</molecular-formula>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 45.3858 -134.41698 0 0
M  V30 2 C 54.83066 -139.86996 0 0
M  V30 3 C 44.24184 -123.53293 0 0
M  V30 4 S 33.53699 -121.25755 0 0
M  V30 5 C 28.06499 -130.73534 0 0
M  V30 6 N 35.38795 -138.8683 0 0
M  V30 7 N 17.21873 -131.87534 0 0
M  V30 8 C 64.27553 -134.41698 0 0 CFG=1
M  V30 9 C 74.67139 -137.83707 0 0 CFG=2
M  V30 10 C 81.1366 -129.00688 0 0
M  V30 11 N 74.73643 -120.12943 0 0
M  V30 12 C 64.31572 -123.47304 0 0
M  V30 13 N 78.0034 -148.2216 0 0
M  V30 14 C 88.0045 -142.53909 0 0
M  V30 15 C 97.40921 -148.13571 0 0
M  V30 16 N 106.9584 -142.78932 0 0
M  V30 17 C 118.32124 -149.09517 0 0
M  V30 18 C 127.87042 -143.74875 0 0
M  V30 19 C 137.27515 -149.34538 0 0
M  V30 20 C 146.82434 -143.99898 0 0
M  V30 21 C 146.96878 -133.05594 0 0
M  V30 22 C 137.56409 -127.45932 0 0
M  V30 23 C 128.01488 -132.80573 0 0
M  V30 24 Cl 156.48483 -127.7281 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 1
M  V30 7 1 5 7
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 8
M  V30 13 1 9 13 CFG=1
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 18
M  V30 25 1 21 24
M  V30 26 1 8 2 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-1" left="5.8999786" right="160.85358" top="110.504425" bottom="157.4966"/>
</substance>
<substance id="1860-5397-5-28-BQWXPTLAMPIGAZ-AAEUAGOBSA-N">
<inchi-key>BQWXPTLAMPIGAZ-AAEUAGOBSA-N</inchi-key>
<inchi>InChI=1S/C18H29N3O5S/c1-17(2,3)25-15(23)20-14-19-12(10-27-14)7-11-8-21(9-13(11)22)16(24)26-18(4,5)6/h10-11,13,22H,7-9H2,1-6H3,(H,19,20,23)/t11-,13-/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)NC1=NC(=CS1)C[C@H]2CN(C[C@@H]2O)C(=O)OC(C)(C)C</smiles>
<extended-smiles>C1[C@@H]([C@H](CN1C(=O)OC(C)(C)C)O)CC2=CSC(=N2)NC(=O)OC(C)(C)C |(332.07,-173,;332.07,-184.52,;343.03,-188.08,;349.8,-178.76,;336.25,-172.01,;325.33,-168.46,;322.94,-157.23,;317.21,-176.58,;306.12,-173.61,;309.1,-162.52,;303.15,-184.69,;295.04,-170.63,;346.58,-199,;322.79,-191.27,;312.3,-186.6,;309.9,-175.33,;298.45,-174.13,;293.76,-184.65,;302.32,-192.36,;282.53,-187.04,;278.98,-197.95,;267.76,-200.34,;286.67,-206.49,;297.9,-204.1,;300.28,-215.33,;295.51,-192.87,;309.12,-201.71,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:23,24,25,8,9,10,13,1,4,16,2,15,3,18,26,11,22,7,19,20,5,14,27,12,21,6,17/E:(1,2,3)(4,5,6)/it:im/rA:27nCC.oC.eCNOCCCCCOCOCCSCNNOCCCCCO/rB:s1;s2;s3;s1s4;;s6;s7;s7;s7;s5s6;d11;P2;N3;s13;d15;s16;s17;s15d18;s18;;s21;s22;s22;s22;s20s21;d26;/rC:332,0739,-172,9995,0;332,0739,-184,5195,0;343,0300,-188,0793,0;349,8013,-178,7595,0;336,2495,-172,0070,0;317,2137,-176,5770,0;306,1249,-173,6058,0;309,0962,-162,5170,0;303,1537,-184,6946,0;295,0361,-170,6345,0;325,3313,-168,4594,0;322,9445,-157,2303,0;322,7864,-191,2672,0;346,5775,-198,9975,0;312,2989,-186,5979,0;309,9037,-175,3297,0;298,4468,-174,1255,0;293,7612,-184,6495,0;302,3223,-192,3579,0;282,5321,-187,0364,0;286,6662,-206,4858,0;297,8953,-204,0990,0;300,2822,-215,3281,0;295,5085,-192,8698,0;309,1245,-201,7121,0;278,9846,-197,9545,0;267,7554,-200,3413,0;</aux-info>
<molecular-formula>C18H29N3O5S</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc,CC(C)(C)OC(=O)N* NHBoc</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 332.07388 -172.99947 0 0
M  V30 2 C 332.07388 -184.51947 0 0 CFG=2
M  V30 3 C 343.03003 -188.07933 0 0 CFG=1
M  V30 4 C 349.80133 -178.75948 0 0
M  V30 5 N 336.24945 -172.00696 0 0
M  V30 6 O 317.21375 -176.57704 0 0
M  V30 7 C 306.12491 -173.60579 0 0
M  V30 8 C 309.09616 -162.51697 0 0
M  V30 9 C 303.15369 -184.69461 0 0
M  V30 10 C 295.03607 -170.63454 0 0
M  V30 11 C 325.33133 -168.45944 0 0
M  V30 12 O 322.94452 -157.2303 0 0
M  V30 13 C 322.78638 -191.26724 0 0
M  V30 14 O 346.57755 -198.99745 0 0
M  V30 15 C 312.29886 -186.59792 0 0
M  V30 16 C 309.90372 -175.32965 0 0
M  V30 17 S 298.44684 -174.12549 0 0
M  V30 18 C 293.76123 -184.64954 0 0
M  V30 19 N 302.32227 -192.35791 0 0
M  V30 20 N 282.5321 -187.03636 0 0
M  V30 21 O 286.6662 -206.48579 0 0
M  V30 22 C 297.89532 -204.09895 0 0
M  V30 23 C 300.28217 -215.32809 0 0
M  V30 24 C 295.50851 -192.86983 0 0
M  V30 25 C 309.12445 -201.71213 0 0
M  V30 26 C 278.98459 -197.95448 0 0
M  V30 27 O 267.75543 -200.34132 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 11
M  V30 5 1 6 7
M  V30 6 1 7 8
M  V30 7 1 7 9
M  V30 8 1 7 10
M  V30 9 2 11 12
M  V30 10 1 6 11
M  V30 11 1 4 5
M  V30 12 1 5 1
M  V30 13 1 2 13 CFG=1
M  V30 14 1 3 14 CFG=3
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 15
M  V30 21 1 20 26
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 22 25
M  V30 26 2 26 27
M  V30 27 1 21 26
M  V30 28 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i1" left="260.2071" right="355.40253" top="159.18959" bottom="202.24745"/>
</substance>
<substance id="1860-5397-5-28-JGBZPLSFZVKDDV-UHFFFAOYSA-N">
<inchi-key>JGBZPLSFZVKDDV-UHFFFAOYSA-N</inchi-key>
<inchi>InChI=1S/C9H14N2O2S/c1-6-5-14-7(10-6)11-8(12)13-9(2,3)4/h5H,1-4H3,(H,10,11,12)</inchi>
<smiles>CC1=CSC(=N1)NC(=O)OC(C)(C)C</smiles>
<extended-smiles>C1=C(N=C(S1)NC(=O)OC(C)(C)C)C |(179.57,-172.1,;183.02,-183.09,;173.63,-189.76,;164.38,-182.9,;168.05,-171.98,;126.48,-136.71,;128.98,-125.5,;139.93,-122.07,;120.52,-117.74,;109.57,-121.17,;106.13,-110.22,;113.01,-132.12,;98.62,-124.61,;193.9,-186.75,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:14,9,10,11,1,2,4,12,8,3,6,13,7,5/E:(2,3,4)/rA:14nCCNCSNOCCCCCOC/rB:d1;s2;d3;s1s4;s4;;s7;s8;s8;s8;s6s7;d12;s2;/rC:179,5679,-172,0956,0;183,0158,-183,0875,0;173,6273,-189,7633,0;164,3770,-182,8972,0;168,0486,-171,9780,0;126,4757,-136,7077,0;120,5246,-117,7352,0;109,5708,-121,1711,0;106,1349,-110,2173,0;113,0067,-132,1248,0;98,6171,-124,6069,0;128,9770,-125,5035,0;139,9308,-122,0676,0;193,8971,-186,7463,0;</aux-info>
<molecular-formula>C9H14N2O2S</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N* NHBoc,C* Me</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 179.56795 -172.09558 0 0
M  V30 2 C 183.01579 -183.08752 0 0
M  V30 3 N 173.62729 -189.76331 0 0
M  V30 4 C 164.37701 -182.89725 0 0
M  V30 5 S 168.04855 -171.97798 0 0
M  V30 6 N 126.47574 -136.70769 0 0
M  V30 7 O 120.52461 -117.73518 0 0
M  V30 8 C 109.57083 -121.17107 0 0
M  V30 9 C 106.13495 -110.2173 0 0
M  V30 10 C 113.00671 -132.12483 0 0
M  V30 11 C 98.61705 -124.60695 0 0
M  V30 12 C 128.97704 -125.50349 0 0
M  V30 13 O 139.93082 -122.06761 0 0
M  V30 14 C 193.89713 -186.74629 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 1
M  V30 6 1 6 12
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 2 12 13
M  V30 12 1 7 12
M  V30 13 1 4 6
M  V30 14 1 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i1" left="131.09824" right="201.63461" top="168.36131" bottom="192.9133"/>
</substance>
<substance id="1860-5397-5-28-NXZIGGBPLGAPTI-UHFFFAOYSA-N">
<inchi-key>NXZIGGBPLGAPTI-UHFFFAOYSA-N</inchi-key>
<inchi>InChI=1S/C9H15NO3/c1-9(2,3)13-8(11)10-4-6-7(5-10)12-6/h6-7H,4-5H2,1-3H3</inchi>
<smiles>CC(C)(C)OC(=O)N1CC2C(C1)O2</smiles>
<extended-smiles>C12C(CN(C(=O)OC(C)(C)C)C1)O2 |(419.66,-205.52,;430.61,-209.12,;437.41,-199.82,;433.17,-198.83,;443.11,-204.57,;443.11,-216.05,;453.05,-198.83,;462.99,-204.57,;457.25,-214.51,;468.73,-194.62,;472.94,-210.31,;419.7,-194,;422.02,-216.8,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:7,8,9,3,12,2,1,10,6,4,11,13,5/E:(1,2,3)(4,5)(6,7)/rA:13nCCCNOCCCCCOCO/rB:s1;s2;s3;;s5;s6;s6;s6;s4s5;d10;s1s4;s1s2;/rC:419,6624,-205,5195,0;430,6054,-209,1196,0;437,4109,-199,8246,0;433,1688,-198,8259,0;453,0527,-198,8259,0;462,9947,-204,5659,0;457,2547,-214,5079,0;468,7347,-194,6240,0;472,9367,-210,3059,0;443,1107,-204,5659,0;443,1107,-216,0459,0;419,7047,-193,9995,0;422,0161,-216,7964,0;</aux-info>
<molecular-formula>C9H15NO3</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 419.66238 -205.51947 0 0
M  V30 2 C 430.60541 -209.11955 0 0
M  V30 3 C 437.41089 -199.82462 0 0
M  V30 4 N 433.16876 -198.82591 0 0
M  V30 5 O 453.05273 -198.82591 0 0
M  V30 6 C 462.99469 -204.56592 0 0
M  V30 7 C 457.2547 -214.50789 0 0
M  V30 8 C 468.73468 -194.62396 0 0
M  V30 9 C 472.93668 -210.30592 0 0
M  V30 10 C 443.11075 -204.56592 0 0
M  V30 11 O 443.11075 -216.04591 0 0
M  V30 12 C 419.70468 -193.99953 0 0
M  V30 13 O 422.01611 -216.79642 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 10
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 6 9
M  V30 8 2 10 11
M  V30 9 1 5 10
M  V30 10 1 3 4
M  V30 11 1 4 12
M  V30 12 1 12 1
M  V30 13 1 1 13
M  V30 14 1 13 2
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i1" left="418.8911" right="441.56134" top="180.22993" bottom="220.04642"/>
<backref ref="1860-5397-5-28-i2" left="44.62599" right="67.29622" top="121.26482" bottom="161.08128"/>
<backref ref="1860-5397-5-28-i4" left="15.770264" right="38.440506" top="120.06482" bottom="159.8813"/>
</substance>
<substance id="1860-5397-5-28-WOADIQNLIXPSIL-ZFWWWQNUSA-N">
<inchi-key>WOADIQNLIXPSIL-ZFWWWQNUSA-N</inchi-key>
<inchi>InChI=1S/C18H34BrNO4Si/c1-17(2,3)23-16(22)20-11-13(9-14(21)10-19)15(12-20)24-25(7,8)18(4,5)6/h13,15H,9-12H2,1-8H3/t13-,15-/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)N1C[C@H](CC(=O)CBr)[C@H](C1)O[Si](C)(C)C(C)(C)C</smiles>
<extended-smiles>[C@H]1([C@H](CN(C(=O)OC(C)(C)C)C1)O[Si](C(C)(C)C)(C)C)CC(CBr)=O |(61,-220.35,;71.94,-223.95,;78.75,-214.66,;74.5,-213.66,;84.45,-219.4,;84.45,-230.88,;94.39,-213.66,;104.33,-219.4,;98.59,-229.34,;110.07,-209.46,;114.27,-225.14,;61.04,-208.83,;75.45,-234.89,;86.67,-237.31,;84.24,-248.53,;95.46,-250.96,;81.81,-259.75,;73.02,-246.11,;89.1,-226.09,;97.89,-239.74,;51.69,-227.07,;41.21,-222.36,;31.24,-228.12,;31.24,-239.64,;40.63,-210.89,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:7,8,9,18,19,20,16,17,21,23,12,3,1,22,2,10,6,15,25,4,24,11,5,13,14/E:(1,2,3)(4,5,6)(7,8)/it:im/rA:25nC.eC.eCNOCCCCCOCOSiCCCCCCCCCOBr/rB:s1;s2;s3;;s5;s6;s6;s6;s4s5;d10;s1s4;N2;s13;s14;s14;s14;s15;s15;s15;P1;s21;s22;d22;s23;/rC:60,9973,-220,3543,0;71,9403,-223,9544,0;78,7457,-214,6595,0;74,5036,-213,6608,0;94,3876,-213,6608,0;104,3296,-219,4008,0;98,5896,-229,3428,0;110,0695,-209,4588,0;114,2715,-225,1408,0;84,4456,-219,4008,0;84,4456,-230,8808,0;61,0396,-208,8344,0;75,4476,-234,8855,0;86,6679,-237,3136,0;84,2399,-248,5339,0;89,0960,-226,0933,0;97,8882,-239,7416,0;95,4602,-250,9619,0;81,8118,-259,7542,0;73,0196,-246,1058,0;51,6850,-227,0680,0;41,2147,-222,3601,0;31,2381,-228,1201,0;40,6350,-210,8948,0;31,2381,-239,6401,0;</aux-info>
<molecular-formula>C18H34BrNO4Si</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc,CC(C)(C)[Si](C)(C)O* OTBS</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 60.99725 -220.35434 0 0 CFG=1
M  V30 2 C 71.94026 -223.95442 0 0 CFG=1
M  V30 3 C 78.74574 -214.65948 0 0
M  V30 4 N 74.50363 -213.66078 0 0
M  V30 5 O 94.38759 -213.66078 0 0
M  V30 6 C 104.32956 -219.40079 0 0
M  V30 7 C 98.58955 -229.34276 0 0
M  V30 8 C 110.06955 -209.45883 0 0
M  V30 9 C 114.27153 -225.14079 0 0
M  V30 10 C 84.4456 -219.40079 0 0
M  V30 11 O 84.4456 -230.88078 0 0
M  V30 12 C 61.03955 -208.8344 0 0
M  V30 13 O 75.44763 -234.8855 0 0
M  V30 14 Si 86.66794 -237.31357 0 0
M  V30 15 C 84.23987 -248.53386 0 0
M  V30 16 C 89.09598 -226.09326 0 0
M  V30 17 C 97.88821 -239.74162 0 0
M  V30 18 C 95.46016 -250.96191 0 0
M  V30 19 C 81.81181 -259.75415 0 0
M  V30 20 C 73.01958 -246.10579 0 0
M  V30 21 C 51.68501 -227.06796 0 0
M  V30 22 C 41.21474 -222.36014 0 0
M  V30 23 C 31.23813 -228.12013 0 0
M  V30 24 O 40.63498 -210.89478 0 0
M  V30 25 Br 31.23813 -239.64012 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 10
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 6 9
M  V30 8 2 10 11
M  V30 9 1 5 10
M  V30 10 1 3 4
M  V30 11 1 4 12
M  V30 12 1 12 1
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 15 18
M  V30 18 1 15 19
M  V30 19 1 15 20
M  V30 20 1 2 13 CFG=3
M  V30 21 1 1 21 CFG=1
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 1 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i2" left="28.425629" right="93.972626" top="195.0648" bottom="242.79012"/>
</substance>
<substance id="1860-5397-5-28-XQMVWBTWHIJCRD-LWEDLAQUSA-N">
<inchi-key>XQMVWBTWHIJCRD-LWEDLAQUSA-N</inchi-key>
<inchi>InChI=1S/C18H35NO4Si/c1-17(2,3)22-16(20)19-10-13(9-14-12-21-14)15(11-19)23-24(7,8)18(4,5)6/h13-15H,9-12H2,1-8H3/t13-,14?,15-/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)N1C[C@H](CC2CO2)[C@H](C1)O[Si](C)(C)C(C)(C)C</smiles>
<extended-smiles>[C@H]1([C@H](CN(C(=O)OC(C)(C)C)C1)O[Si](C(C)(C)C)(C)C)CC2CO2 |(239.2,-144.15,;250.14,-147.75,;256.95,-138.46,;252.7,-137.46,;262.65,-143.2,;262.65,-154.68,;272.59,-137.46,;282.53,-143.2,;276.79,-153.14,;288.27,-133.26,;292.47,-148.94,;239.24,-132.63,;253.65,-158.69,;264.87,-161.11,;262.44,-172.33,;273.66,-174.76,;260.01,-183.55,;251.22,-169.91,;267.3,-149.89,;276.09,-163.54,;229.89,-150.87,;219.41,-146.16,;209.44,-151.92,;209.44,-140.4,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:7,8,9,18,19,20,16,17,21,12,3,23,1,22,2,10,6,15,4,11,24,5,13,14/E:(1,2,3)(4,5,6)(7,8)/it:im/rA:24nC.eC.eCNOCCCCCOCOSiCCCCCCCCCO/rB:s1;s2;s3;;s5;s6;s6;s6;s4s5;d10;s1s4;N2;s13;s14;s14;s14;s15;s15;s15;P1;s21;s22;s22s23;/rC:239,1973,-144,1543,0;250,1403,-147,7544,0;256,9457,-138,4595,0;252,7036,-137,4608,0;272,5876,-137,4608,0;282,5295,-143,2008,0;276,7896,-153,1428,0;288,2696,-133,2588,0;292,4715,-148,9408,0;262,6456,-143,2008,0;262,6456,-154,6808,0;239,2395,-132,6344,0;253,6476,-158,6855,0;264,8679,-161,1136,0;262,4399,-172,3338,0;267,2960,-149,8933,0;276,0882,-163,5416,0;273,6602,-174,7619,0;260,0118,-183,5541,0;251,2196,-169,9058,0;229,8850,-150,8680,0;219,4147,-146,1601,0;209,4381,-151,9201,0;209,4381,-140,4001,0;</aux-info>
<molecular-formula>C18H35NO4Si</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc,CC(C)(C)[Si](C)(C)O* OTBS</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 239.19725 -144.15434 0 0 CFG=1
M  V30 2 C 250.14026 -147.75443 0 0 CFG=1
M  V30 3 C 256.94574 -138.45949 0 0
M  V30 4 N 252.70364 -137.46078 0 0
M  V30 5 O 272.58759 -137.46078 0 0
M  V30 6 C 282.52954 -143.20079 0 0
M  V30 7 C 276.78955 -153.14276 0 0
M  V30 8 C 288.26956 -133.25883 0 0
M  V30 9 C 292.47153 -148.94078 0 0
M  V30 10 C 262.6456 -143.20079 0 0
M  V30 11 O 262.6456 -154.68079 0 0
M  V30 12 C 239.23955 -132.6344 0 0
M  V30 13 O 253.64763 -158.6855 0 0
M  V30 14 Si 264.86792 -161.11357 0 0
M  V30 15 C 262.43988 -172.33385 0 0
M  V30 16 C 267.29599 -149.89326 0 0
M  V30 17 C 276.08823 -163.54161 0 0
M  V30 18 C 273.66016 -174.76192 0 0
M  V30 19 C 260.01181 -183.55414 0 0
M  V30 20 C 251.21957 -169.90579 0 0
M  V30 21 C 229.88501 -150.86797 0 0
M  V30 22 C 219.41473 -146.16014 0 0
M  V30 23 C 209.43813 -151.92014 0 0
M  V30 24 O 209.43813 -140.40013 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 10
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 6 9
M  V30 8 2 10 11
M  V30 9 1 5 10
M  V30 10 1 3 4
M  V30 11 1 4 12
M  V30 12 1 12 1
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 14 17
M  V30 17 1 15 18
M  V30 18 1 15 19
M  V30 19 1 15 20
M  V30 20 1 2 13 CFG=3
M  V30 21 1 1 21 CFG=1
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 1 24 23
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i2" left="206.31313" right="272.1726" top="118.86481" bottom="161.9355"/>
</substance>
<substance id="1860-5397-5-28-NTNZTEQNFHNYBC-UHFFFAOYSA-N">
<inchi-key>NTNZTEQNFHNYBC-UHFFFAOYSA-N</inchi-key>
<inchi>InChI=1S/C4H9NO2/c1-2-7-4(6)3-5/h2-3,5H2,1H3</inchi>
<smiles>CCOC(=O)CN</smiles>
<extended-smiles>C(CN)(=O)OCC |(43.86,-114.37,;53.76,-120.27,;53.76,-131.79,;43.86,-102.85,;33.89,-120.13,;33.89,-131.63,;43.85,-137.38,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:5,6,2,1,7,3,4/rA:7nCCOOCCN/rB:s1;d1;s1;;s4s5;s2;/rC:43,8634,-114,3743,0;53,7631,-120,2655,0;43,8634,-102,8544,0;33,8868,-120,1343,0;43,8460,-137,3843,0;33,8867,-131,6343,0;53,7631,-131,7855,0;</aux-info>
<molecular-formula>C4H9NO2</molecular-formula>
<abbreviations>CCO* OEt</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 43.86337 -114.37434 0 0
M  V30 2 C 53.76306 -120.26553 0 0
M  V30 3 O 43.86337 -102.85435 0 0
M  V30 4 O 33.88676 -120.13434 0 0
M  V30 5 C 43.84604 -137.38434 0 0
M  V30 6 C 33.88675 -131.63432 0 0
M  V30 7 N 53.76306 -131.78552 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 4 6
M  V30 4 1 5 6
M  V30 5 1 1 4
M  V30 6 1 2 7
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i3" left="23.311752" right="65.68805" top="99.237686" bottom="136.63551"/>
</substance>
<substance id="1860-5397-5-28-VZTVSBDNMGBNQD-UHFFFAOYSA-N">
<inchi-key>VZTVSBDNMGBNQD-UHFFFAOYSA-N</inchi-key>
<inchi>InChI=1S/C14H18ClNO3/c1-14(2,3)19-13(18)16(8-9-17)10-11-4-6-12(15)7-5-11/h4-7,9H,8,10H2,1-3H3</inchi>
<smiles>CC(C)(C)OC(=O)N(CC([H])=O)CC1=CC=C(C=C1)Cl</smiles>
<extended-smiles>C(CN(C(=O)OC(C)(C)C)CC1=CC=C(C=C1)Cl)(=O)[H] |(36.36,-196.12,;46.26,-202.02,;56.31,-196.39,;66.2,-202.27,;76.08,-208.15,;72.08,-192.39,;83.58,-192.54,;95.08,-192.69,;89.2,-202.57,;89.46,-182.66,;68.28,-203.03,;78.33,-197.4,;88.23,-203.29,;98.28,-197.66,;98.43,-186.14,;88.53,-180.25,;78.48,-185.88,;108.45,-180.53,;36.36,-184.6,;26.39,-201.88,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:6,7,8,13,17,14,16,2,1,11,12,15,9,5,18,3,19,10,4/E:(1,2,3)(4,5)(6,7)/rA:20nCCNOCCCCCOCCCCCCCClOH/rB:s1;s2;;s4;s5;s5;s5;s3s4;d9;s3;s11;d12;s13;d14;s15;s12d16;s15;d1;s1;/rC:36,3634,-196,1243,0;46,2631,-202,0155,0;56,3148,-196,3877,0;72,0783,-192,3862,0;83,5773,-192,5380,0;95,0763,-192,6898,0;89,1954,-202,5724,0;89,4583,-182,6555,0;66,1974,-202,2687,0;76,0799,-208,1497,0;68,2757,-203,0255,0;78,3275,-197,3977,0;88,2272,-203,2889,0;98,2790,-197,6611,0;98,4310,-186,1421,0;88,5314,-180,2509,0;78,4796,-185,8787,0;108,4479,-180,5338,0;36,3634,-184,6044,0;26,3868,-201,8843,0;</aux-info>
<molecular-formula>C14H18ClNO3</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 36.36337 -196.12434 0 0
M  V30 2 C 46.26306 -202.01553 0 0
M  V30 3 N 56.31485 -196.38774 0 0
M  V30 4 O 72.07834 -192.3862 0 0
M  V30 5 C 83.57733 -192.53802 0 0
M  V30 6 C 95.07634 -192.68983 0 0
M  V30 7 C 89.19536 -202.57236 0 0
M  V30 8 C 89.45831 -182.6555 0 0
M  V30 9 C 66.19736 -202.26872 0 0
M  V30 10 O 76.07988 -208.14969 0 0
M  V30 11 C 68.27574 -203.02548 0 0
M  V30 12 C 78.3275 -197.39767 0 0
M  V30 13 C 88.22722 -203.28886 0 0
M  V30 14 C 98.27899 -197.66107 0 0
M  V30 15 C 98.43105 -186.14207 0 0
M  V30 16 C 88.53136 -180.2509 0 0
M  V30 17 C 78.47957 -185.87869 0 0
M  V30 18 Cl 108.44794 -180.53383 0 0
M  V30 19 O 36.36337 -184.60435 0 0
M  V30 20 H 26.38676 -201.88434 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 9
M  V30 3 1 4 5
M  V30 4 1 5 6
M  V30 5 1 5 7
M  V30 6 1 5 8
M  V30 7 2 9 10
M  V30 8 1 4 9
M  V30 9 1 2 3
M  V30 10 1 3 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 12
M  V30 18 1 15 18
M  V30 19 2 1 19
M  V30 20 1 1 20
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i3" left="23.511765" right="113.07294" top="176.91716" bottom="205.03433"/>
</substance>
<substance id="1860-5397-5-28-WJECGFAXKRDMFI-WIOPSUGQSA-N">
<inchi-key>WJECGFAXKRDMFI-WIOPSUGQSA-N</inchi-key>
<inchi>InChI=1S/C32H48ClN5O6S/c1-30(2,3)42-27(39)36-26-35-24(20-45-26)16-22-18-38(29(41)44-32(7,8)9)19-25(22)34-14-15-37(28(40)43-31(4,5)6)17-21-10-12-23(33)13-11-21/h10-13,20,22,25,34H,14-19H2,1-9H3,(H,35,36,39)/t22-,25+/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)NC1=NC(=CS1)C[C@H]2CN(C[C@H]2NCCN(CC3=CC=C(C=C3)Cl)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C</smiles>
<extended-smiles>C1(C[C@@H]2[C@@H](CN(C(=O)OC(C)(C)C)C2)NCCN(C(=O)OC(C)(C)C)CC3=CC=C(C=C3)Cl)=CSC(=N1)NC(=O)OC(C)(C)C |(221,-192.82,;230.94,-198.56,;240.89,-192.82,;251.83,-196.42,;258.63,-187.13,;251.9,-177.79,;240.46,-178.95,;239.3,-167.5,;229.01,-180.11,;224.3,-190.59,;219.58,-201.08,;231.02,-199.92,;212.86,-191.75,;240.93,-181.3,;255.34,-207.36,;265.86,-201.37,;275.76,-207.27,;285.81,-201.64,;295.7,-207.52,;305.58,-213.4,;301.58,-197.64,;313.08,-197.79,;324.58,-197.94,;318.7,-207.82,;318.96,-187.91,;297.78,-208.28,;307.83,-202.65,;317.73,-208.54,;327.78,-202.91,;327.93,-191.39,;318.03,-185.5,;307.98,-191.13,;337.95,-185.78,;219.8,-181.37,;208.53,-178.97,;202.77,-188.95,;210.48,-197.51,;191.35,-190.15,;186.67,-200.66,;176.17,-195.98,;182,-211.16,;188.76,-220.46,;195.52,-229.77,;200.19,-219.26,;184.08,-230.97,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:10,11,12,33,34,35,21,22,23,40,44,41,43,28,29,2,38,26,17,3,39,15,42,1,16,5,13,36,24,9,32,20,45,27,6,7,30,18,14,37,25,8,31,19,4/E:(1,2,3)(4,5,6)(7,8,9)(10,11)(12,13)/it:im/rA:45nCCCSCNNOCCCCCOC.eC.oCNOCCCCCOCNCCNOCCCCCOCCCCCCCCl/rB:s1;d1;s3;s4;s1d5;s5;;s8;s9;s9;s9;s7s8;d13;p2;s15;s16;s17;;s19;s20;s20;s20;s18s19;d24;s15s18;P16;s27;s28;s29;;s31;s32;s32;s32;s30s31;d36;s30;s38;d39;s40;d41;s42;s39d43;s42;/rC:221,0016,-192,8248,0;230,9435,-198,5647,0;219,7974,-181,3679,0;208,5291,-178,9727,0;202,7691,-188,9493,0;210,4775,-197,5104,0;191,3521,-190,1493,0;181,9971,-211,1609,0;188,7567,-220,4646,0;195,5162,-229,7683,0;200,1937,-219,2625,0;184,0792,-230,9704,0;186,6746,-200,6551,0;176,1688,-195,9776,0;240,8855,-192,8248,0;251,8285,-196,4249,0;258,6340,-187,1299,0;251,8970,-177,7852,0;229,0143,-180,1054,0;224,2983,-190,5939,0;219,5823,-201,0824,0;231,0236,-199,9223,0;212,8569,-191,7540,0;240,4556,-178,9453,0;239,2956,-167,5040,0;240,9278,-181,3048,0;255,3359,-207,3559,0;265,8634,-201,3743,0;275,7631,-207,2655,0;285,8148,-201,6377,0;301,5783,-197,6362,0;313,0773,-197,7880,0;324,5764,-197,9398,0;318,6954,-207,8224,0;318,9583,-187,9055,0;295,6974,-207,5187,0;305,5799,-213,3997,0;297,7758,-208,2755,0;307,8275,-202,6477,0;317,7272,-208,5389,0;327,7790,-202,9111,0;327,9310,-191,3921,0;318,0314,-185,5009,0;307,9796,-191,1287,0;337,9479,-185,7838,0;</aux-info>
<molecular-formula>C32H48ClN5O6S</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc,CC(C)(C)OC(=O)N* NHBoc</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 221.00159 -192.82475 0 0
M  V30 2 C 230.94354 -198.56474 0 0
M  V30 3 C 219.79741 -181.36786 0 0
M  V30 4 S 208.52914 -178.97273 0 0
M  V30 5 C 202.76915 -188.94934 0 0
M  V30 6 N 210.47754 -197.51036 0 0
M  V30 7 N 191.35205 -190.14934 0 0
M  V30 8 O 181.99713 -211.16089 0 0
M  V30 9 C 188.75667 -220.46458 0 0
M  V30 10 C 195.5162 -229.76826 0 0
M  V30 11 C 200.19366 -219.2625 0 0
M  V30 12 C 184.07921 -230.97035 0 0
M  V30 13 C 186.67459 -200.65512 0 0
M  V30 14 O 176.16881 -195.97765 0 0
M  V30 15 C 240.88551 -192.82475 0 0 CFG=1
M  V30 16 C 251.82852 -196.42485 0 0 CFG=2
M  V30 17 C 258.634 -187.12991 0 0
M  V30 18 N 251.89699 -177.78523 0 0
M  V30 19 O 229.01431 -180.10536 0 0
M  V30 20 C 224.29829 -190.59389 0 0
M  V30 21 C 219.58226 -201.08241 0 0
M  V30 22 C 231.02361 -199.92235 0 0
M  V30 23 C 212.85695 -191.75395 0 0
M  V30 24 C 240.45564 -178.9453 0 0
M  V30 25 O 239.29558 -167.50397 0 0
M  V30 26 C 240.92781 -181.30482 0 0
M  V30 27 N 255.33591 -207.35594 0 0
M  V30 28 C 265.86337 -201.37434 0 0
M  V30 29 C 275.76306 -207.26553 0 0
M  V30 30 N 285.81485 -201.63774 0 0
M  V30 31 O 301.57834 -197.6362 0 0
M  V30 32 C 313.07733 -197.78802 0 0
M  V30 33 C 324.57635 -197.93983 0 0
M  V30 34 C 318.69537 -207.82236 0 0
M  V30 35 C 318.95831 -187.9055 0 0
M  V30 36 C 295.69736 -207.51872 0 0
M  V30 37 O 305.5799 -213.39969 0 0
M  V30 38 C 297.77576 -208.27548 0 0
M  V30 39 C 307.82751 -202.64767 0 0
M  V30 40 C 317.72723 -208.53886 0 0
M  V30 41 C 327.77899 -202.91107 0 0
M  V30 42 C 327.93103 -191.39207 0 0
M  V30 43 C 318.03137 -185.5009 0 0
M  V30 44 C 307.97955 -191.12869 0 0
M  V30 45 Cl 337.94794 -185.78383 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 1
M  V30 7 1 7 13
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 12 2 13 14
M  V30 13 1 8 13
M  V30 14 1 5 7
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 18 24
M  V30 18 1 19 20
M  V30 19 1 20 21
M  V30 20 1 20 22
M  V30 21 1 20 23
M  V30 22 2 24 25
M  V30 23 1 19 24
M  V30 24 1 17 18
M  V30 25 1 18 26
M  V30 26 1 26 15
M  V30 27 1 16 27 CFG=1
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 30 36
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 32 34
M  V30 34 1 32 35
M  V30 35 2 36 37
M  V30 36 1 31 36
M  V30 37 1 29 30
M  V30 38 1 30 38
M  V30 39 1 38 39
M  V30 40 2 39 40
M  V30 41 1 40 41
M  V30 42 2 41 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 44 39
M  V30 46 1 42 45
M  V30 47 1 15 2 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i3" left="169.02704" right="342.57294" top="167.53523" bottom="217.15593"/>
</substance>
<substance id="1860-5397-5-28-BWAZFZNRWMXPLN-YUMQZZPRSA-N">
<inchi-key>BWAZFZNRWMXPLN-YUMQZZPRSA-N</inchi-key>
<inchi>InChI=1S/C11H20N2O3S/c1-11(2,3)16-10(15)13-5-7(4-9(12)17)8(14)6-13/h7-8,14H,4-6H2,1-3H3,(H2,12,17)/t7-,8-/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)N1C[C@H](CC(=S)N)[C@H](C1)O</smiles>
<extended-smiles>[C@H]1([C@H](CN(C(=O)OC(C)(C)C)C1)O)CC(=S)N |(215.14,-143.55,;226.08,-147.15,;232.89,-137.86,;228.65,-136.86,;238.59,-142.6,;238.59,-154.08,;248.53,-136.86,;258.47,-142.6,;252.73,-152.54,;264.21,-132.66,;268.42,-148.34,;215.18,-132.03,;229.59,-158.09,;205.83,-150.27,;195.36,-145.56,;194.2,-134.14,;186.05,-152.27,)|</extended-smiles>
<aux-info>AuxInfo=1/1/N:7,8,9,14,12,3,1,2,15,10,6,17,4,13,11,5,16/E:(1,2,3)/it:im/rA:17nC.eC.eCNOCCCCCOCOCCSN/rB:s1;s2;s3;;s5;s6;s6;s6;s4s5;d10;s1s4;N2;P1;s14;d15;s15;/rC:215,1415,-143,5544,0;226,0845,-147,1544,0;232,8900,-137,8595,0;228,6479,-136,8608,0;248,5319,-136,8608,0;258,4738,-142,6008,0;252,7338,-152,5428,0;264,2138,-132,6588,0;268,4158,-148,3408,0;238,5899,-142,6008,0;238,5899,-154,0808,0;215,1838,-132,0344,0;229,5919,-158,0855,0;205,8293,-150,2680,0;195,3590,-145,5602,0;194,2010,-134,1387,0;186,0468,-152,2738,0;</aux-info>
<molecular-formula>C11H20N2O3S</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 215.14153 -143.55435 0 0 CFG=1
M  V30 2 C 226.08453 -147.15443 0 0 CFG=1
M  V30 3 C 232.89001 -137.8595 0 0
M  V30 4 N 228.64792 -136.86079 0 0
M  V30 5 O 248.53186 -136.86079 0 0
M  V30 6 C 258.47382 -142.6008 0 0
M  V30 7 C 252.73383 -152.54277 0 0
M  V30 8 C 264.21384 -132.65884 0 0
M  V30 9 C 268.41583 -148.34081 0 0
M  V30 10 C 238.58989 -142.6008 0 0
M  V30 11 O 238.58989 -154.0808 0 0
M  V30 12 C 215.18382 -132.03441 0 0
M  V30 13 O 229.5919 -158.08551 0 0
M  V30 14 C 205.82928 -150.26797 0 0
M  V30 15 C 195.35901 -145.56015 0 0
M  V30 16 S 194.20097 -134.1387 0 0
M  V30 17 N 186.04677 -152.27376 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 10
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 6 9
M  V30 8 2 10 11
M  V30 9 1 5 10
M  V30 10 1 3 4
M  V30 11 1 4 12
M  V30 12 1 12 1
M  V30 13 1 2 13 CFG=3
M  V30 14 1 1 14 CFG=1
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i4" left="174.12177" right="238.4169" top="118.26482" bottom="161.33551"/>
</substance>
<substance id="1860-5397-5-28-CHZMTYJWURGDSB-IUCAKERBSA-N">
<inchi-key>CHZMTYJWURGDSB-IUCAKERBSA-N</inchi-key>
<inchi>InChI=1S/C11H18N2O3/c1-11(2,3)16-10(15)13-6-8(4-5-12)9(14)7-13/h8-9,14H,4,6-7H2,1-3H3/t8-,9-/m0/s1</inchi>
<smiles>CC(C)(C)OC(=O)N1C[C@H](CC#N)[C@H](C1)O</smiles>
<extended-smiles>[C@H]1([C@H](CN(C(=O)OC(C)(C)C)C1)O)CC#N |(112.54,-143.55,;123.48,-147.15,;130.29,-137.86,;126.05,-136.86,;135.99,-142.6,;135.99,-154.08,;145.93,-136.86,;155.87,-142.6,;150.13,-152.54,;161.61,-132.66,;165.82,-148.34,;112.58,-132.03,;126.99,-158.09,;103.23,-150.27,;92.76,-145.56,;82.29,-140.85,)|</extended-smiles>
<aux-info>AuxInfo=1/0/N:7,8,9,14,15,12,3,1,2,10,6,16,4,13,11,5/E:(1,2,3)/it:im/rA:16nC.eC.eCNOCCCCCOCOCCN/rB:s1;s2;s3;;s5;s6;s6;s6;s4s5;d10;s1s4;N2;P1;s14;t15;/rC:112,5415,-143,5544,0;123,4845,-147,1544,0;130,2900,-137,8595,0;126,0479,-136,8608,0;145,9319,-136,8608,0;155,8738,-142,6008,0;150,1338,-152,5428,0;161,6138,-132,6588,0;165,8158,-148,3408,0;135,9899,-142,6008,0;135,9899,-154,0808,0;112,5838,-132,0344,0;126,9919,-158,0855,0;103,2293,-150,2680,0;92,7590,-145,5602,0;82,2887,-140,8523,0;</aux-info>
<molecular-formula>C11H18N2O3</molecular-formula>
<abbreviations>CC(C)(C)OC(=O)N(*)* NBoc,C(#N)* CN</abbreviations>
<molfile>
  CDK     04242619112D

  0  0  0     0  0            999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 112.54153 -143.55435 0 0 CFG=1
M  V30 2 C 123.48454 -147.15443 0 0 CFG=1
M  V30 3 C 130.29002 -137.8595 0 0
M  V30 4 N 126.04791 -136.86079 0 0
M  V30 5 O 145.93187 -136.86079 0 0
M  V30 6 C 155.87383 -142.6008 0 0
M  V30 7 C 150.13383 -152.54277 0 0
M  V30 8 C 161.61383 -132.65884 0 0
M  V30 9 C 165.81581 -148.34081 0 0
M  V30 10 C 135.98988 -142.6008 0 0
M  V30 11 O 135.98988 -154.0808 0 0
M  V30 12 C 112.58383 -132.03441 0 0
M  V30 13 O 126.99191 -158.08551 0 0
M  V30 14 C 103.22929 -150.26797 0 0
M  V30 15 C 92.75902 -145.56015 0 0
M  V30 16 N 82.28874 -140.85233 0 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 10
M  V30 4 1 5 6
M  V30 5 1 6 7
M  V30 6 1 6 8
M  V30 7 1 6 9
M  V30 8 2 10 11
M  V30 9 1 5 10
M  V30 10 1 3 4
M  V30 11 1 4 12
M  V30 12 1 12 1
M  V30 13 1 2 13 CFG=3
M  V30 14 1 1 14 CFG=1
M  V30 15 3 15 16
M  V30 16 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
</molfile>
<backref ref="1860-5397-5-28-i4" left="84.13402" right="135.81691" top="118.26482" bottom="161.33551"/>
</substance>
</substances>
<supporting-information>
<paragraph>
<chunk>Supporting Information features full experimental details for all synthetic steps, characterization of intermediates (</chunk>
<chunk superscript="yes">1</chunk>
<chunk>H NMR, </chunk>
<chunk superscript="yes">13</chunk>
<chunk>C NMR, ESMS), details of Autodock analysis, details of in vitro enzyme assay, and HPLC chromatograms for determining purity of compound </chunk>
<chunk bold="yes">3</chunk>
<chunk>.</chunk>
</paragraph>
<supporting-information-file id="si1" public-id="1860-5397-5-28-S1">
<caption>
<paragraph>
<chunk>Experimental and analytical data</chunk>
</paragraph>
</caption>
</supporting-information-file>
</supporting-information>
<end-section>
<title>
<chunk>Acknowledgements</chunk>
</title>
<paragraph>
<chunk>The authors are grateful to the National Institutes of Health (GM49725 to R.B.S. and GM52419 to Professor Bettie Sue Siler Masters, with whose laboratory P.M. and L.J.R. are associated) for financial support of this research. B.S.S.M. also is grateful to the Welch Foundation for a Robert A. Welch Foundation Distinguished Professorship in Chemistry (AQ0012). P.M. is supported by grants 0021620806 and 1M0520 from MSMT of the Czech Republic. We thank Marc Sala for preliminary studies on the synthesis of </chunk>
<chunk bold="yes">6</chunk>
<chunk>.</chunk>
</paragraph>
</end-section>
<reference id="b1" type="article" volume="109" first-page="33" last-page="41">
<reference-author first-name="L" last-name="Zhang"/>
<reference-author first-name="V" middle-names="L" last-name="Dawson"/>
<reference-author first-name="T" middle-names="M" last-name="Dawson"/>
<source>
<chunk>Pharmacol. Ther.</chunk>
</source>
<publication-date year="2006"/>
<external-link type="doi" public-id="10.1016/j.pharmthera.2005.05.007"/>
</reference>
<reference id="b2" type="article" volume="205" first-page="659" last-page="665">
<reference-author first-name="M" middle-names="A" last-name="Dorheim"/>
<reference-author first-name="W" middle-names="R" last-name="Tracey"/>
<reference-author first-name="J" middle-names="S" last-name="Pollock"/>
<reference-author first-name="P" last-name="Grammas"/>
<source>
<chunk>Biochem. Biophys. Res. Commun.</chunk>
</source>
<publication-date year="1994"/>
<external-link type="doi" public-id="10.1006/bbrc.1994.2716"/>
</reference>
<reference id="b3" type="article" volume="40" first-page="511" last-page="526">
<reference-author first-name="N" middle-names="R" last-name="Sims"/>
<reference-author first-name="M" middle-names="F" last-name="Anderson"/>
<source>
<chunk>Neurochem. Int.</chunk>
</source>
<publication-date year="2002"/>
<external-link type="doi" public-id="10.1016/S0197-0186(01)00122-X"/>
</reference>
<reference id="b4" type="article" volume="3" first-page="64" last-page="71">
<reference-author first-name="D" middle-names="M" last-name="Ferriero"/>
<reference-author first-name="D" middle-names="M" last-name="Holtzman"/>
<reference-author first-name="S" middle-names="M" last-name="Black"/>
<reference-author first-name="R" middle-names="A" last-name="Sheldon"/>
<source>
<chunk>Neurobiol. Dis.</chunk>
</source>
<publication-date year="1996"/>
<external-link type="doi" public-id="10.1006/nbdi.1996.0006"/>
</reference>
<reference id="b5" type="article" volume="105" first-page="483" last-page="489">
<reference-author first-name="J" last-name="Zicha"/>
<reference-author first-name="O" last-name="Pecha&#328;ov&#225;"/>
<reference-author first-name="Z" last-name="Dobe&#353;ov&#225;"/>
<reference-author last-name="Kune&#353;"/>
<source>
<chunk>J. Clin. Sci.</chunk>
</source>
<publication-date year="2003"/>
<external-link type="doi" public-id="10.1042/CS20030078"/>
</reference>
<reference id="b6" type="article" volume="5" first-page="603" last-page="624">
<reference-author first-name="E" middle-names="P" last-name="Erdal"/>
<reference-author first-name="E" middle-names="A" last-name="Litzinger"/>
<reference-author first-name="J" middle-names="W" last-name="Seo"/>
<reference-author first-name="Y" middle-names="Q" last-name="Zhu"/>
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<source>
<chunk>Curr. Top. Med. Chem.</chunk>
</source>
<publication-date year="2005"/>
<external-link type="doi" public-id="10.2174/1568026054679317"/>
</reference>
<reference id="b7" type="article" volume="33" first-page="32" last-page="41">
<reference-author first-name="A" last-name="Seelig"/>
<source>
<chunk>J. Mol. Neurosci.</chunk>
</source>
<publication-date year="2007"/>
<external-link type="doi" public-id="10.1007/s12031-007-0055-y"/>
</reference>
<reference id="b8" type="article" volume="130" first-page="3900" last-page="3914">
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="B" middle-names="Z" last-name="Stanton"/>
<reference-author first-name="J" last-name="Igarashi"/>
<reference-author first-name="H" last-name="Li"/>
<reference-author first-name="P" last-name="Mart&#225;sek"/>
<reference-author first-name="L" middle-names="J" last-name="Roman"/>
<reference-author first-name="T" middle-names="L" last-name="Poulos"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<source>
<chunk>J. Am. Chem. Soc.</chunk>
</source>
<publication-date year="2008"/>
<external-link type="doi" public-id="10.1021/ja0772041"/>
</reference>
<reference id="b9" type="article" volume="52" first-page="779" last-page="797">
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="H" last-name="Li"/>
<reference-author first-name="P" last-name="Mart&#225;sek"/>
<reference-author first-name="L" middle-names="J" last-name="Roman"/>
<reference-author first-name="T" middle-names="L" last-name="Poulos"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<source>
<chunk>J. Med. Chem.</chunk>
</source>
<publication-date year="2009"/>
<external-link type="doi" public-id="10.1021/jm801220a"/>
</reference>
<reference id="b10" type="article" volume="65" first-page="209" last-page="217">
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="S" last-name="Tan"/>
<reference-author first-name="J" last-name="Igarashi"/>
<reference-author first-name="H" last-name="Li"/>
<reference-author first-name="M" last-name="Derrick"/>
<reference-author first-name="P" last-name="Mart&#225;sek"/>
<reference-author first-name="L" middle-names="J" last-name="Roman"/>
<reference-author first-name="J" last-name="V&#225;squez-Vivar"/>
<reference-author first-name="T" middle-names="L" last-name="Poulos"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<source>
<chunk>Ann. Neurol.</chunk>
</source>
<publication-date year="2009"/>
<external-link type="doi" public-id="10.1002/ana.21555"/>
</reference>
<reference id="b11" type="article" volume="5" first-page="1513" last-page="1522">
<reference-author first-name="M" last-name="Schmidt am Busch"/>
<reference-author first-name="E" middle-names="W" last-name="Knapp"/>
<source>
<chunk>ChemPhysChem</chunk>
</source>
<publication-date year="2004"/>
<external-link type="doi" public-id="10.1002/cphc.200400171"/>
</reference>
<reference id="b12" type="article" volume="52" in-press="yes">
<reference-author first-name="J" last-name="Igarashi"/>
<reference-author first-name="H" last-name="Li"/>
<reference-author first-name="J" last-name="Jamal"/>
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="J" last-name="Fang"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<reference-author first-name="T" middle-names="L" last-name="Poulos"/>
<source>
<chunk>J. Med. Chem.</chunk>
</source>
<publication-date year="2009"/>
</reference>
<reference id="b13" type="article" volume="13" first-page="1901" last-page="1910">
<reference-author first-name="P" last-name="Allevi"/>
<reference-author first-name="M" last-name="Galligani"/>
<reference-author first-name="M" last-name="Anastasia"/>
<source>
<chunk>Tetrahedron: Asymmetry</chunk>
</source>
<publication-date year="2002"/>
<external-link type="doi" public-id="10.1016/S0957-4166(02)00477-9"/>
</reference>
<reference id="b14" type="article" volume="26" first-page="2173" last-page="2176">
<reference-author first-name="T" middle-names="R" last-name="Kelly"/>
<reference-author first-name="N" middle-names="S" last-name="Chandrakumar"/>
<reference-author first-name="J" middle-names="D" last-name="Cutting"/>
<reference-author first-name="R" middle-names="R" last-name="Goehring"/>
<reference-author first-name="F" middle-names="R" last-name="Weibel"/>
<source>
<chunk>Tetrahedron Lett.</chunk>
</source>
<publication-date year="1985"/>
<external-link type="doi" public-id="10.1016/S0040-4039(00)98954-8"/>
</reference>
<reference id="b15" type="article" first-page="2615" last-page="2617">
<reference-author first-name="M" middle-names="C" last-name="Bagley"/>
<reference-author first-name="K" last-name="Chapaneri"/>
<reference-author first-name="C" last-name="Glover"/>
<reference-author first-name="E" middle-names="A" last-name="Merritt"/>
<source>
<chunk>Synlett</chunk>
</source>
<publication-date year="2004"/>
<external-link type="doi" public-id="10.1055/s-2004-834812"/>
</reference>
<reference id="b16" type="article" first-page="159" last-page="164">
<reference-author first-name="A" last-name="Barton"/>
<reference-author first-name="S" middle-names="P" last-name="Breukelman"/>
<reference-author first-name="P" middle-names="T" last-name="Kaye"/>
<reference-author first-name="G" middle-names="D" last-name="Meakins"/>
<reference-author first-name="D" middle-names="J" last-name="Morgan"/>
<source>
<chunk>J. Chem. Soc., Perkin Trans. 1</chunk>
</source>
<publication-date year="1982"/>
</reference>
<reference id="b17" type="article" volume="61" first-page="1257" last-page="1267">
<reference-author first-name="L" last-name="Dudin"/>
<reference-author first-name="G" last-name="Pattenden"/>
<reference-author first-name="M" middle-names="S" last-name="Viljoen"/>
<reference-author first-name="C" last-name="Wilson"/>
<source>
<chunk>Tetrahedron</chunk>
</source>
<publication-date year="2005"/>
<external-link type="doi" public-id="10.1016/j.tet.2004.11.032"/>
</reference>
<reference id="b18" type="article" first-page="1704" last-page="1710">
<reference-author first-name="R" middle-names="M" last-name="van Well"/>
<reference-author first-name="H" middle-names="S" last-name="Overkleeft"/>
<reference-author first-name="J" middle-names="H" last-name="van Boom"/>
<reference-author first-name="A" last-name="Coop"/>
<reference-author first-name="J" middle-names="B" last-name="Wang"/>
<reference-author first-name="H" middle-names="Y" last-name="Wang"/>
<reference-author first-name="G" middle-names="A" last-name="van der Marel"/>
<reference-author first-name="M" last-name="Overhand"/>
<source>
<chunk>Eur. J. Org. Chem.</chunk>
</source>
<publication-date year="2003"/>
<external-link type="doi" public-id="10.1002/ejoc.200210682"/>
</reference>
<reference id="b19" type="article" volume="47" first-page="6113" last-page="6115">
<reference-author first-name="G" middle-names="R" last-name="Lawton"/>
<reference-author first-name="H" last-name="Ji"/>
<reference-author first-name="R" middle-names="B" last-name="Silverman"/>
<source>
<chunk>Tetrahedron Lett.</chunk>
</source>
<publication-date year="2006"/>
<external-link type="doi" public-id="10.1016/j.tetlet.2006.06.091"/>
</reference>
<reference id="b20" type="article" volume="76" first-page="1866" last-page="1870">
<reference-author first-name="E" middle-names="C" last-name="Taylor"/>
<reference-author first-name="J" last-name="Wolinsky"/>
<reference-author first-name="H" middle-names="H" last-name="Lee"/>
<source>
<chunk>J. Am. Chem. Soc.</chunk>
</source>
<publication-date year="1954"/>
<external-link type="doi" public-id="10.1021/ja01636a038"/>
</reference>
<reference id="b21" type="article" volume="92" first-page="8428" last-page="8432">
<reference-author first-name="L" middle-names="J" last-name="Roman"/>
<reference-author first-name="E" middle-names="A" last-name="Sheta"/>
<reference-author first-name="P" last-name="Martasek"/>
<reference-author first-name="S" middle-names="S" last-name="Gross"/>
<reference-author first-name="Q" last-name="Liu"/>
<reference-author first-name="B" middle-names="S S" last-name="Masters"/>
<source>
<chunk>Proc. Natl. Acad. Sci. U. S. A.</chunk>
</source>
<publication-date year="1995"/>
<external-link type="doi" public-id="10.1073/pnas.92.18.8428"/>
</reference>
<reference id="b22" type="article" volume="219" first-page="359" last-page="365">
<reference-author first-name="P" last-name="Mart&#225;sek"/>
<reference-author first-name="Q" last-name="Liu"/>
<reference-author first-name="J" middle-names="W" last-name="Liu"/>
<reference-author first-name="L" middle-names="J" last-name="Roman"/>
<reference-author first-name="S" middle-names="S" last-name="Gross"/>
<reference-author first-name="W" middle-names="C" last-name="Sessa"/>
<reference-author first-name="B" middle-names="S S" last-name="Masters"/>
<source>
<chunk>Biochem. Biophys. Res. Commun.</chunk>
</source>
<publication-date year="1996"/>
<external-link type="doi" public-id="10.1006/bbrc.1996.0238"/>
</reference>
<reference id="b23" type="article" volume="266" first-page="22789" last-page="22791">
<reference-author first-name="J" middle-names="M" last-name="Hevel"/>
<reference-author first-name="K" middle-names="A" last-name="White"/>
<reference-author first-name="M" middle-names="A" last-name="Marletta"/>
<source>
<chunk>J. Biol. Chem.</chunk>
</source>
<publication-date year="1991"/>
</reference>
<reference id="b24" type="article" volume="233" first-page="250" last-page="258">
<reference-author first-name="J" middle-names="M" last-name="Hevel"/>
<reference-author first-name="M" middle-names="A" last-name="Marletta"/>
<source>
<chunk>Method Enzymol.</chunk>
</source>
<publication-date year="1994"/>
<external-link type="doi" public-id="10.1016/S0076-6879(94)33028-X"/>
</reference>
<reference id="b25" type="article" volume="10" first-page="1975" last-page="1978">
<reference-author first-name="W" middle-names="H" last-name="Hagmann"/>
<reference-author first-name="C" middle-names="G" last-name="Caldwell"/>
<reference-author first-name="P" last-name="Chen"/>
<reference-author first-name="P" middle-names="L" last-name="Durette"/>
<reference-author first-name="C" middle-names="K" last-name="Esser"/>
<reference-author first-name="T" middle-names="J" last-name="Lanza"/>
<reference-author first-name="I" middle-names="E" last-name="Kopka"/>
<reference-author first-name="R" last-name="Guthikonda"/>
<reference-author first-name="S" middle-names="K" last-name="Shah"/>
<reference-author first-name="M" last-name="MacCoss"/>
<reference-author first-name="R" middle-names="M" last-name="Chabin"/>
<reference-author first-name="D" last-name="Fletcher"/>
<reference-author first-name="S" middle-names="K" last-name="Grant"/>
<reference-author first-name="B" middle-names="G" last-name="Green"/>
<reference-author first-name="J" middle-names="L" last-name="Humes"/>
<reference-author first-name="T" middle-names="M" last-name="Kelly"/>
<reference-author first-name="S" last-name="Luell"/>
<reference-author first-name="R" last-name="Meurer"/>
<reference-author first-name="V" last-name="Moore"/>
<reference-author first-name="S" middle-names="G" last-name="Pacholok"/>
<reference-author first-name="T" last-name="Pavia"/>
<reference-author first-name="H" middle-names="R" last-name="Williams"/>
<reference-author first-name="K" middle-names="K" last-name="Wong"/>
<source>
<chunk>Bioorg. Med. Chem. Lett.</chunk>
</source>
<publication-date year="2000"/>
<external-link type="doi" public-id="10.1016/S0960-894X(00)00389-9"/>
</reference>
<copyright year="2009" holder="Lawton et al; licensee Beilstein-Institut." link="http://creativecommons.org/licenses/by/2.0">
<paragraph>
<chunk>This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</chunk>
</paragraph>
<paragraph>
<chunk>The license is subject to the </chunk>
<chunk italic="yes">Beilstein Journal of Organic Chemistry</chunk>
<chunk> terms and conditions: (http://www.beilstein-journals.org/bjoc)</chunk>
</paragraph>
</copyright>
</article>
